|
|
|
| Algal Polysaccharides Inhibits Proliferation and Migration of Liver Cancer Cell Hep3B Via Down-regulation of EMP Pathway |
| FENG Yuan1, TANG Yun2, XU Lei3, TAN Hai-gang4 |
1. Key Laboratory of Functional Protein Research of Guangzhou Higher Education Institutes, Institute of Life and Health Engineering, Jinan University, Guangzhou 510632, China;
2. Key Laboratory of Food and Nutrition Safety of Ministry of Education, College of Food Science and Biotechnology, Tanjin University of Science and Technology, Tianjin 300222, China;
3. College of Life Science and Technology, Shanghai Jiao Tong University, Shanghai 200240, China;
4. College of Food Science and Engineering, Qingdao Agricultural Unviersity, Qingdao 266109, China |
|
|
|
Abstract Objective:To investigate the effort of algal polysaccharides(AP) on the ability of proliferation and migration in the liver cancer cell line Hep3B and potential mechanism which may provide a new idea for treatment of liver cancer.Methhods:①Four different cell lines were selected to compare the metabolic levels of embden-meyerhof-parnas(EMP) pathway in normal cells and cancer cells.②To detect the EMP metabolic levels changes in Hep3B with AP treatment.③MTT, qPCR and Transwell were used to measure the ability of cell proliferation,EMT marker and cell migration respectively in Hep3B cell with AP treatment.④Measured the ability of cell viability,proliferation and EMT Pathway with inhibitor:3-bromopyruvate(3-BrPA). ⑤Measured EMP levels and Akt signal pathway changes with AP or 3-BrPA treatment. ⑥Detected Akt signal pathway,cell viability and migration changes with AP and 3-BrPA treatment. Result:①The metabolic levels of EMP in cancer cells(Hep3B,HeLa,SW480)are higher than normal cell(HL02).Hep3B cell EMP metabolic level is the highest in three cancer cell lines. ②AP down regulated metabolic levels in Hep3B cell and it was concentration-dependent. ③AP inhibited the ability of proliferation and migration in Hep3B and down regulated the EMT progress. ④3-BrPA inhibited HK activity and down regulated the cell viability rate and migration ability compared with control group(P<0.01). ⑤AP and 3-BrPA both down regulated the EMP levels and inhibited Akt signal pathway. ⑥In AP + 3-BrPA group, HK activity was depressed obviously compared with AP group, and cell viability and wound healing rate were decreased seriously. Conclusion:The metabolic level of EMP pathway in Hep3B is much higher than normal cell. AP could down regulated Hep3B cell EMP metabolism level. Low metabolism levels of EMP could inhibit the proliferation and migration of Hep3B via down-regulation of EMT progress and Akt signaling pathway. When Hep3B was co-treated with AP and 3-BrPA,the cell ability and migration ability were depressed more obviously than only AP treatment. These data show AP therapy was effective on liver cancer cell Hep3B.
|
|
Received: 06 April 2017
Published: 25 September 2017
|
|
|
|
|
[1] Wijesekara I, Pangestuti R, Kim S K. Biological activities and potential health benefits of sulfated polysaccharides derived from marine algae. Carbohydrate Polymers, 2011, 84(1):14-21.
[2] Lee J C, Hou M F, Huang H W, et al. Marine algal natural products with anti-oxidative, anti-inflammatory, and anti-cancer properties. Cancer Cell International, 2013, 13(1):55.
[3] Kim J, Dang C V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Research, 2006, 66(18):8927-8930.
[4] Porporato P E, Dhup S, Dadhich R K, et al. Anticancer targets in the glycolytic metabolism of tumors:a comprehensive review. Frontiers in Pharmacology, 2011, 7(2):2.
[5] Altenberg B, Greulich K O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics, 2004, 84(6):1014-1020.
[6] Gatenby R A, Gillies R J. Glycolysis in cancer:a potential target for therapy. The International Journal of Biochemistry & Cell Biology, 2007, 39(7):1358-1366.
[7] Heimbach J, Kulik L M, Finn R, et al. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2017,209(78):124-128.
[8] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2016, 150(4):835-853.
[9] Noy R, Pollard J W. Tumor-associated macrophages:from mechanisms to therapy. Immunity, 2014, 41(1):49-61.
[10] Nilsson H, Lindgren D, Forsberg A M, et al. Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate. Cell Death & Disease, 2015, 6(1):e1585.
[11] Xintaropoulou C, Ward C, Wise A, et al. A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models. Oncotarget, 2015, 6(28):25677.
[12] Ganapathy-Kanniappan S, Geschwind J F H. Tumor glycolysis as a target for cancer therapy:progress and prospects. Molecular Cancer, 2013, 12(1):152.
[13] Costa L S, Fidelis G P, Cordeiro S L, et al. Biological activities of sulfated polysaccharides from tropical seaweeds. Biomedicine & Pharmacotherapy, 2010, 64(1):21-28.
[14] Zong A, Cao H, Wang F. Anticancer polysaccharides from natural resources:A review of recent research. Carbohydrate Polymers, 2012, 90(4):1395-1410.
[15] Shoshan M C. 3-Bromopyruvate:targets and outcomes. Journal of Bioenergetics and Biomembranes, 2012, 44(1):7-15.
[16] Zheng J. Energy metabolism of cancer:Glycolysis versus oxidative phosphorylation (review). Oncology Letters, 2012, 4(6):1151-1157.
[17] Liu Z, Zhang Y Y, Zhang Q W, et al. 3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway. Anti-cancer Drugs, 2014, 25(4):447-455.
[18] Ha G H, Park J S, Breuer E K Y. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Letters, 2013, 332(1):63-73. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
